Long-term outcomes of infliximab in patients with Beh?et's disease-associated uveitis
Long-term outcomes of infliximab in patients with Beh?et's disease-associated uveitis
复制标题
英夫利昔单抗治疗白塞氏病相关葡萄膜炎患者的长期结果
DOI：
10.1007/s10792-022-02495-z
复制
发表时间：
2022
影响因子：
1.6
通讯作者：
Sonoda Koh-Hei
中科院分区：
文献类型：
--
作者：
Yamana Satoshi;Hasegawa Eiichi;Takeda Atsunobu;Yawata Nobuyo;Sonoda Koh-Hei
ObjectivesTo evaluate long-term outcomes of infliximab（IFX）treatment in patients with Behçet's disease（BD）-associated uveitis.Patients and Methods我们回顾性分析了用IFX治疗超过5年的BD相关性葡萄膜炎患者的病例。我们比较了眼炎症发作，眼部疾病的活动，视力之前和之后开始IFX treatment.ResultsThe 24例患者20名男性和4名女性。开始IFX治疗时的平均年龄为37.3 ± 9.2岁。IFX治疗开始后的平均时间为10.3 ± 2.4年。在IFX治疗前，眼部炎症发作的平均次数为每12个月5.4 ± 2.1次，并且在开始IFX治疗后显著降低为每12个月0.83 ± 0.96次（p< 0.05）。我们使用了一种名为白塞病眼部发作评分24（BOS 24）的BD相关葡萄膜炎评分系统来估计IFX治疗前后眼部疾病活动度的变化。开始IFX治疗后，平均评分从7.58 ± 2.77显著降低至2.55 ± 2.74（p< 0.05）。即使在治疗> 5年后，眼部发作次数和BOS 24评分仍持续下降。42的48眼（24例）的视力得到改善或maintained.ConclusionsIFX是有效的控制眼部炎症发作和减少眼部疾病的活动与BD相关性葡萄膜炎患者，它保持了患者的视力。
ObjectivesTo evaluate long-term outcomes of infliximab (IFX) treatment in patients with Behçet's disease (BD)-associated uveitis.Patients and methodsWe retrospectively analyzed the cases of patients with BD-associated uveitis treated with IFX for > 5 years. We compared the numbers of ocular inflammatory attacks, ocular disease activities, and visual acuity before and after the initiation of IFX treatment.ResultsThe 24 patients were 20 men and 4 women. Their mean age at the initiation of IFX treatment was 37.3 ± 9.2 years. The mean term from the initiation of IFX treatment was 10.3 ± 2.4 years. The average number of ocular inflammatory attacks was 5.4 ± 2.1 per 12 months before the IFX treatment and significantly lower at 0.83 ± 0.96 per 12 months after the initiation of IFX treatment (p< 0.05). We used a scoring system for BD-associated uveitis named the Behçet's disease ocular attack score 24 (BOS24) to estimate the changes in ocular disease activities between before and after initiation of IFX treatment. The average score decreased significantly from 7.58 ± 2.77 to 2.55 ± 2.74 after the initiation of IFX treatment (p< 0.05). Even after > 5 years of the treatment, both the number of ocular attacks and the BOS24 score kept decreasing. The visual acuity in 42 of 48 eyes (24 patients) was improved or maintained.ConclusionsIFX was effective for controlling ocular inflammatory attacks and diminishing ocular disease activities in patients with BD-associated uveitis, and it maintained the patients' visual acuity.